Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Logos Global Management LP

Q2 2023 · 13F-HR

Logos Global Management LPholdings as filed

Filed 2023-08-14 · accession 0001172661-23-003013

$735.2M
Reported value
51
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$56.9M7.74%625,000CommonSOLE
23282W605CYTKCYTOKINETICS INC$53.8M7.32%1,650,000CommonSOLE
45258J102IMVTIMMUNOVANT INC$42.7M5.81%2,250,000CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$41.1M5.59%1,750,000CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$34.4M4.67%300,000CommonSOLE
68062P106OLMAOLEMA PHARMACEUTICALS INC$33.8M4.60%3,743,875CommonSOLE
45258D105IMCRIMMUNOCORE HLDGS PLC$30.0M4.08%500,000CommonSOLE
09062X103BIIBBIOGEN INC$28.5M3.87%100,000CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$28.3M3.85%300,000CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$26.8M3.64%1,125,000CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$24.3M3.30%520,000CommonSOLE
01671P100ALLKGUSDALLAKOS INC$22.9M3.11%5,250,000CommonSOLE
45114M109ICOSAVAX INC$21.5M2.93%2,165,741CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$20.0M2.72%1,780,000CommonSOLE
25056L103DSGNDESIGN THERAPEUTICS INC$17.6M2.40%2,797,501CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$16.6M2.26%400,000CommonSOLE
03940C100ACLXGBXARCELLX INC$15.8M2.15%500,000CommonSOLE
03969F109RCUSARCUS BIOSCIENCES INC$15.2M2.07%750,000CommonSOLE
088786108BCYCBICYCLE THERAPEUTICS PLC$13.3M1.80%520,000CommonSOLE
03589W102ANNXANNEXON INC$12.3M1.68%3,500,000CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$11.2M1.52%650,000CALLSOLE
98420N105XENEXENON PHARMACEUTICALS INC$10.6M1.44%275,000CommonSOLE
36315X101LKFTGALAPAGOS NV$10.2M1.38%250,000CommonSOLE
19240Q201COGTCOGENT BIOSCIENCES INC$9.5M1.29%800,000CommonSOLE
59045L106MERSANA THERAPEUTICS INC$9.2M1.25%2,800,000CommonSOLE
617760202MOR2MORPHOSYS AG$9.0M1.22%1,200,000CommonSOLE
09061G101BMRNBIOMARIN PHARMACEUTICAL INC$8.7M1.18%100,000CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$8.2M1.12%250,000CommonSOLE
23954D109DAWNGBXDAY ONE BIOPHARMACEUTICALS I$7.8M1.06%650,000CommonSOLE
48576A100KARUNA THERAPEUTICS INC$7.6M1.03%35,000CommonSOLE
00166B105ALXOALX ONCOLOGY HLDGS INC$7.5M1.02%1,000,000CommonSOLE
374163103GERNGERON CORP$7.1M0.96%2,200,000CommonSOLE
24661P807DCTHDELCATH SYS INC$6.9M0.93%1,178,787CommonSOLE
38406L103GRACELL BIOTECHNOLOGIES INC$6.9M0.93%1,800,000CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$6.3M0.85%307,076CommonSOLE
N44445109IMTXIMMATICS N.V$5.8M0.78%500,000CommonSOLE
56854Q200MRNS*MARINUS PHARMACEUTICALS INC$5.7M0.78%525,000CommonSOLE
00461U105ACRSACLARIS THERAPEUTICS INC$5.4M0.74%525,000CommonSOLE
50127T109KURAKURA ONCOLOGY INC$5.3M0.72%500,000CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$5.2M0.70%300,000CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$5.0M0.68%250,000CommonSOLE
92764N102VIRVIR BIOTECHNOLOGY INC$4.9M0.67%200,000CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$4.5M0.62%544,960CommonSOLE
87990A106TNYATENAYA THERAPEUTICS INC$3.5M0.48%600,000CommonSOLE
23306J101DBV TECHNOLOGIES S A$2.3M0.31%1,200,000CommonSOLE
92673K108VIGLVIGIL NEUROSCIENCE INC$1.8M0.24%188,390CommonSOLE
00773J103AEGLEA BIOTHERAPEUTICS INC$1.4M0.19%3,142,880CommonSOLE
4525EP101VTLUSDIMMUNIC INC$1.1M0.14%421,184CommonSOLE
53000N108LIANYLIANBIO$638,4000.09%280,000CommonSOLE
90240B106TYRATYRA BIOSCIENCES INC$542,7800.07%31,872CommonSOLE
67080N119NUVB/WSNUVATION BIO INC$11,0270.00%66,666CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.